Compare GNT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | BDSX |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.7M | 153.3M |
| IPO Year | N/A | 2020 |
| Metric | GNT | BDSX |
|---|---|---|
| Price | $8.19 | $20.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 129.2K | 91.9K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | $8.62 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $6.22 | $0.33 |
| 52 Week High | $9.30 | $24.92 |
| Indicator | GNT | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 54.37 |
| Support Level | $8.17 | $18.91 |
| Resistance Level | $8.35 | $24.92 |
| Average True Range (ATR) | 0.08 | 1.98 |
| MACD | 0.00 | -0.39 |
| Stochastic Oscillator | 52.50 | 27.97 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.